India, July 22 -- Repligen Corp. (RGEN), a life sciences company, on Wednesday agreed to acquire BioLife Solutions Inc. (BLFS) in cash-and-stock deal at approximately $1.5 billion, expanding its presence in the fast-growing cell therapy market.
The acquisition is expected to close in the fourth quarter of 2026.
The deal is valued at $31 per share, representing a 24% premium to BioLife's 90-day volume-weighted average price through July 21.
Under the agreement, BioLife shareholders will receive $11.25 in cash and 0.1442 of the company's shares for each BioLife share.
The transaction is expected to be accretive to Repligen's revenue growth, adjusted margins, and adjusted earnings per share, contributing at least $0.05 per share in the fir...